Pharmacologic Management of Bone-related Complications and Bone Metastases in Postmenopausal Women with Hormone Receptor-positive Breast Cancer

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2016 May 25

PMID 27217795

Citations 16

Authors

Denise A Yardley

Affiliations

Soon will be listed here.

Abstract

There is a high risk for bone loss and skeletal-related events, including bone metastases, in postmenopausal women with hormone receptor-positive breast cancer. Both the disease itself and its therapeutic treatments can negatively impact bone, resulting in decreases in bone mineral density and increases in bone loss. These negative effects on the bone can significantly impact morbidity and mortality. Effective management and minimization of bone-related complications in postmenopausal women with hormone receptor-positive breast cancer remain essential. This review discusses the current understanding of molecular and biological mechanisms involved in bone turnover and metastases, increased risk for bone-related complications from breast cancer and breast cancer therapy, and current and emerging treatment strategies for managing bone metastases and bone turnover in postmenopausal women with hormone receptor-positive breast cancer.

Citing Articles

Preoperative platelet distribution width predicts bone metastasis in patients with breast cancer.

Song M, Zhao L, Huang W, Cui M, Liu Y, Wang R BMC Cancer. 2024; 24(1):1066.

PMID: 39210343 PMC: 11360324. DOI: 10.1186/s12885-024-12837-y.

IBSP Promotes Breast Cancer Bone Metastasis and Proliferation via BMP-SMAD Signaling Pathway.

Ding W, Lv D, Wang M, Pei D Cancer Rep (Hoboken). 2024; 7(8):e2153.

PMID: 39118232 PMC: 11310091. DOI: 10.1002/cnr2.2153.

Ghrelin Induces the Production of Hypothalamic NPY Through the AMPK-mTOR Pathway to Alleviate Cancer-induced Bone Pain.

Xu L, Hou L, Cao C, Li X In Vivo. 2024; 38(3):1133-1142.

PMID: 38688635 PMC: 11059913. DOI: 10.21873/invivo.13548.

The role played by ailanthone in inhibiting bone metastasis of breast cancer by regulating tumor-bone microenvironment through the RANKL-dependent pathway.

Wang Y, Zhong Z, Ma M, Zhao Y, Zhang C, Qian Z Front Pharmacol. 2023; 13:1081978.

PMID: 36686653 PMC: 9849906. DOI: 10.3389/fphar.2022.1081978.

Predicting Response to Radiotherapy in Breast Cancer-Induced Bone Pain: Relationship Between Pain and Serum Cytokine Expression Levels After Radiotherapy.

Lou Y, Cao H, Wang R, Chen Y, Zhang H J Pain Res. 2022; 15:3555-3562.

PMID: 36394055 PMC: 9664930. DOI: 10.2147/JPR.S387670.

References

Gralow J, Biermann J, Farooki A, Fornier M, Gagel R, Kumar R . NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw. 2013; 11 Suppl 3:S1-50. DOI: 10.6004/jnccn.2013.0215. View

Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P . Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2012; 24(2):398-405. DOI: 10.1093/annonc/mds277. View

Chavez-MacGregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E . Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer. 2011; 118(2):326-32. PMC: 3158806. DOI: 10.1002/cncr.26144. View

Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M . Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010; 11(5):421-8. PMC: 3792651. DOI: 10.1016/S1470-2045(10)70054-1. View

Mundy G . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2(8):584-93. DOI: 10.1038/nrc867. View

Powles T, Hickish T, Kanis J, Tidy A, Ashley S . Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996; 14(1):78-84. DOI: 10.1200/JCO.1996.14.1.78. View

Body J, Diel I, Lichinitser M, Kreuser E, Dornoff W, Gorbunova V . Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003; 14(9):1399-405. DOI: 10.1093/annonc/mdg367. View

Clemons M, Gelmon K, Pritchard K, Paterson A . Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol. 2012; 19(5):259-68. PMC: 3457877. DOI: 10.3747/co.19.1011. View

Fuleihan G, Salamoun M, Abou Mourad Y, Chehal A, Salem Z, Mahfoud Z . Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2005; 90(6):3209-14. DOI: 10.1210/jc.2004-1444. View

10.

Miller T, Hennessy B, Gonzalez-Angulo A, Fox E, Mills G, Chen H . Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest. 2010; 120(7):2406-13. PMC: 2898598. DOI: 10.1172/JCI41680. View

11.

Baselga J, Campone M, Piccart M, Burris 3rd H, Rugo H, Sahmoud T . Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2011; 366(6):520-9. PMC: 5705195. DOI: 10.1056/NEJMoa1109653. View

12.

Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S . Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer. 2006; 13(2):137-44. DOI: 10.2325/jbcs.13.137. View

13.

Coleman R, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M . Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011; 365(15):1396-405. DOI: 10.1056/NEJMoa1105195. View

14.

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M . Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008; 26(10):1664-70. DOI: 10.1200/JCO.2007.13.5822. View

15.

Rosen L, Gordon D, Dugan Jr W, Major P, Eisenberg P, Provencher L . Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2003; 100(1):36-43. DOI: 10.1002/cncr.11892. View

16.

Theriault R, Lipton A, Hortobagyi G, Leff R, Gluck S, Stewart J . Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999; 17(3):846-54. DOI: 10.1200/JCO.1999.17.3.846. View

17.

Ottewell P, Deux B, Monkkonen H, Cross S, Coleman R, Clezardin P . Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008; 14(14):4658-66. DOI: 10.1158/1078-0432.CCR-07-1545. View

18.

Costa L, Harper P, Coleman R, Lipton A . Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol. 2011; 77 Suppl 1:S31-7. DOI: 10.1016/S1040-8428(11)70006-3. View

19.

Forbes J, Cuzick J, Buzdar A, Howell A, Tobias J, Baum M . Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2007; 9(1):45-53. DOI: 10.1016/S1470-2045(07)70385-6. View

20.

Miller P, Bolognese M, Lewiecki E, McClung M, Ding B, Austin M . Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43(2):222-229. DOI: 10.1016/j.bone.2008.04.007. View